The article by Shen et al entitled “Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study” (Journal of Clinical Oncology 10.1200/JCO.21.01926) was published online April 20, 2022, with errors.
The TEAEs and TRAEs leading to death reported in Table 3 include those that were due to disease progression, contrary to footnote ‘a’. Additionally, it has been noted that an incorrect reference (reference 21) was included in the reference list.
This has been corrected as of December 19, 2023. The authors apologize for the errors.